Navigation Links
Celgosivir in Medical News

MIGENIX Reports Preliminary Celgosivir Viral Kinetics Study

VANCOUVER, and SAN DIEGO, Dec. 3 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI, OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, has received preliminary four-week interim results from a Phase II viral kinetics study in hepatitis C virus ("HCV") treatment-naive patie...

New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report

...erferon II-58 Nautilus Biotech Commences Phase I Study for Belerofon(R) II-58 Migenix Announces Phase II Proof-of-Concept Study Results of celgosivir II-59 Pharmasset Begins Multiple Dose-Escalating Study of R7128 II-59 Transgene Commences Phase I Trial of TG4040 II-59 Debiopharm Release...
Celgosivir in Medical Technology

New Clinical Study Results Indicate Higher Early Virologic Response with Celgosivir Combination Therapy in HCV Non-Responders

Data to be Presented April 15th at EASL Conference in Barcelona, Spain VANCOUVER and SAN DIEGO, CA, April 11, 2007 /PRNewswire-FirstCall/ - MIGENIX Inc. , a clinical-stage developer of drugs for infectious diseases, has received new top-line results confirming the previously announced clinical res...

Migenix to Present Celgosivir Phase II Hepatitis C Results at Digestive Disease Week 2007

VANCOUVER and SAN DIEGO, May 18, 2007 /PRNewswire-FirstCall/ - MIGENIX Inc. , a clinical-stage developer of drugs for infectious diseases will make a presentation of results from a recent hepatitis C Phase II combination therapy study (see April 11, 2007 press release) in a non-responder patient p...

Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting

...bination With Peginterferon Alfa-2b in Treatment-Naive Patients With Chronic HCV; E.S. Maller, Monday, May 21, 2:15 p.m., Room 206 Phase II Study of celgosivir in combination with Peginterferon alfa-2b and ribavirin in chronic hepatitis C genotype 1 nonresponder patients; K.D. Kaita, Monday, May 21, 2:45 p.m....
Celgosivir in Biological Technology

MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study

VANCOUVER and SAN DIEGO, Jan. 31 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI, OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, will add a 600mg celgosivir combination therapy arm to its currently enrolling Phase II viral kinetics study in hepatitis C virus ("HCV") ...

MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting

VANCOUVER and SAN DIEGO, Sept. 10 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases will present results of viral resistance studies with its anti-HCV agent celgosivir at the 14th International Symposium on Hepatitis C Vir...

MIGENIX Reports First Quarter Fiscal 2009 Financial Results

...cal study program (previously Cutanea was targeting the end of 2008). celgosivir (MX-3253; oral alpha-glucosidase I inhibitor; treatment of chronic hepatiti...e are continuing to seek strategic options for advancing the development of celgosivir and are currently in key partnering discussions. MX-2401 (IV lipopeptide;...

MIGENIX Corporate Update and Requisition of Special Meeting

...ayments and a single-digit royalty on net sales. celgosivir (oral alpha-glucosidase inhibitor for Hepatitis C ...rus infections): A Phase II study assessing 400 mg celgosivir for tolerability, pharmacokinetics and viral kinet...pment by the end of 2008; to have results from the celgosivir Phase II viral kinetics study in the next several ...

Migenix Takes Operational Actions To Extend Cash Past Upcoming Key Milestones

...nt payment(s), milestones and royalty terms celgosivir (hepatitis C virus): ----------------------------... - Program-related: The planned extension of the celgosivir viral kinetics study to include a 600 mg celgosivir combination arm (600 mg ...

MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results

...such a partnership(s) is uncertain at this time. celgosivir (MX-3253; oral alpha-glucosidase I inhibitor; trea...y is currently enrolling patients to assess 600 mg celgosivir for tolerability, pharmacokinetics and viral kinet... to the standard of care drugs alone and to 400 mg celgosivir plus the standard of care for up to 12 weeks of th...

MIGENIX releases CEO message #22

...n H2/08 - NDA submission in H1/09 - Rest of world partnership celgosivir (hepatitis C virus): - Phase II viral kinetics study results (includi... application (NDA) being submitted for OmigardTM in the first half of 2009; celgosivir Phase II viral kinetic results in the third quarter 2008; CLS001 entering i...

MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results

...) for omiganan 1% gel in the first half of 2009. celgosivir (MX-3253; oral alpha-glucosidase I inhibitor; trea...ncept and evidence of clinical benefit when adding celgosivir to the current standard-of-care HCV therapy (pegyl... (SVR). The safety profile for patients exposed to celgosivir for up to 48 weeks did not differ from those in th...

MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification

... Company to Report Interim celgosivir 4-Week Viral Kinetics Study Data on Monday December ...ort interim 4-week data from a Phase II viral kinetics combination study of celgosivir in patients with chronic HCV (genotype 1) infection on Monday December 3, 2...

MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference

... Company Provides Revised Timing on Interim celgosivir Viral Kinetics Study ... prevention of catheter-related infections - celgosivir - a Phase II product candidate for treating chroni...rom a Phase II viral kinetics combination study of celgosivir in patients with chronic HCV (genotype 1) infectio...
Other Tags
(Date:3/5/2015)... At the 7th Annual Mississippi Addiction Conference ... met today in Jackson, Mississippi to listen to keynote ... numerous respected speakers will be William S. Jacobs, ... pain medications have had in today’s opiate overdose and ... is hard to believe that much of the current ...
(Date:3/5/2015)... University of Western States (UWS), ... has launched a new center of excellence to ... Northwest Center for Lifestyle and Functional Medicine aim ... and conduct research in the areas of lifestyle ... The center will target efforts on the UWS ...
(Date:3/5/2015)... NY (PRWEB) March 05, 2015 Dr. ... Surgeon ( http://www.orthopedicsurgeonnyc.com ) has been named by ... New York Metro area. Dr. Glashow has been selected ... authoritative guide to the top specialty care doctors in ... The prestigious Castle Connolly program, which carefully screens and ...
(Date:3/5/2015)... 05, 2015 Today, Earth Source ... on 100% pollution-free electricity through a partnership with ... As an Arcadia Power Clean Energy Partner, ESO ... Power Partnership requirements, joining national brands such as ... clean energy. Earth Source Organics joins a growing ...
(Date:3/5/2015)... Think it’s tough to get kids to ... them to brush their teeth. That’s a finding from a ... Delta Dental(1) in conjunction with National Parenting Month in March. ... kids to brush their teeth is one of the most ... higher than getting children to eat vegetables regularly (42 percent) ...
Breaking Medicine News(10 mins):Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 3Health News:University of Western States Launches Northwest Center for Lifestyle and Functional Medicine 2Health News:Dr. Jonathan Glashow, NYC Orthopedic Surgeon, Named Top Doctor: New York Metro Area 2Health News:Earth Source Organics to Run on Clean Energy from Arcadia Power 2Health News:Delta Dental Survey Says Parents Have Harder Time Getting Kids to Brush than to Eat Vegetables 2Health News:Delta Dental Survey Says Parents Have Harder Time Getting Kids to Brush than to Eat Vegetables 3
(Date:2/10/2015)... -- Alere Inc. (NYSE: ALR), a global leader in ... quarter ended December 31, 2014. Namal ... said, "We made substantial progress in the fourth ... in rapid diagnostics and delivering against our financial ... early January enabled us to substantially reduce our ...
(Date:2/5/2015)... DIEGO , Jan. 26, 2015   Epic Sciences ... of cancer, today announced that Murali Prahalad , Ph.D., ... Personalized Medicine World Conference (PMWC) 2015: Silicon Valley, which ... Mountain View, Calif. on January 26-28, 2015. ... "CTCs Come of Age as Biomarkers." Last year, Epic Sciences ...
(Date:2/5/2015)... , Jan. 28, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... upcoming RedChip Global Online CEO Conference on January 29 ... Gino Pereira , CEO of NXT-ID will present ... product, the Wocket smart wallet and its full suite ...
Breaking Biology News(10 mins):Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35Alere Inc. Announces Fourth Quarter 2014 Results 36
Other Contents